tiprankstipranks
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
US Market
IKT
Inhibikase Therapeutics
RESEARCH TOOLSreports

Inhibikase Therapeutics (IKT) Financial Statements

Compare
380 Followers

Inhibikase Therapeutics Financial Overview

Inhibikase Therapeutics's market cap is currently $221.81M. The company's EPS TTM is $-0.1; its P/E ratio is -4.18; Inhibikase Therapeutics is scheduled to report earnings on March 26, 2026, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 25Dec 24Dec 23Mar 23Mar 22
Income Statement
Total Revenue$ 0.00$ 0.00$ 260.50K$ 123.44K$ 3.10M
Gross Profit$ -60.50K$ -26.27K$ -13.36M$ 116.72K$ -8.26M
Operating Income$ -53.35M$ -28.59M$ -20.09M$ -18.13M$ -14.77M
EBITDA$ -51.97M$ -27.49M$ -19.91M$ -18.05M$ 0.00
Net Income$ -48.26M$ -27.52M$ -19.03M$ -18.05M$ -14.79M
Balance Sheet
Cash & Short-Term Investments$ 178.76M$ 97.54M$ 13.25M$ 23.05M$ 40.75M
Total Assets$ 181.20M$ 98.60M$ 14.51M$ 24.94M$ 42.47M
Total Debt$ 0.00$ 110.52K$ 622.00K$ 351.29K$ 248.91K
Net Debt$ -139.22M$ -56.38M$ -8.54M$ -6.84M$ -40.50M
Total Liabilities$ 8.30M$ 3.73M$ 3.53M$ 3.90M$ 4.05M
Stockholders' Equity$ 172.90M$ 94.87M$ 10.98M$ 21.04M$ 38.42M
Cash Flow
Free Cash Flow$ -27.79M$ -19.15M$ -18.10M$ -17.59M$ -14.30M
Operating Cash Flow$ -27.79M$ -19.15M$ -18.09M$ -17.35M$ -14.30M
Investing Cash Flow$ 2.05M$ -37.00M$ 11.66M$ -16.01M$ 0.00
Financing Cash Flow$ 108.46M$ 103.48M$ 8.41M$ -204.77K$ 41.09M
Currency in USD

Inhibikase Therapeutics Earnings and Revenue History

Income Statement >

Inhibikase Therapeutics Debt to Assets

Balance Sheet >

Inhibikase Therapeutics Cash Flow

Cash Flow >

Inhibikase Therapeutics Forecast EPS vs Actual EPS

Earnings >